Pharmaceutical News and Articles

Alzheimer’s Drug Can Be Safely Administered In Memory Clinics, Study Says

THURSDAY, May 15, 2025 The 2023 approval of the first drug shown to slow the progression of Alzheimer s disease came with no small amount of concern from skepti

Study Finds No Link Between COVID Vaccine And Miscarriage Risk

THURSDAY, May 15, 2025 There s no link between the COVID-19 vaccine and miscarriage, a new study says. COVID poses significant risks to pregnant women, includin

FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

OSAKA, Japan and CAMBRIDGE, Massachusetts, May 14, 2025 Takeda (TSE 4502 NYSE TAK) today announced that the New England Journal of Medicine published data from

FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

Pathological Fatigue Common Up to 12 Months After TIA

Pathological fatigue is common up to 12 months after a diagnosis of transient ischemic attack (TIA), according to a study published online May 14 in Neurology.

CDC: Drug Overdose Deaths Down More Than 25 Percent in 2024

Drug overdose deaths decreased by 26.9 percent from 2023 to 2024, according to provisional data released today from the National Center for Health Statistics. A

Multitarget Stool DNA Tests More Costly Than FIT for Colorectal Cancer Detection

Multitarget stool DNA test (MSDT)- and next-generation MSDT (N-G MSDT)-based screening have higher costs per detected advanced neoplasia case or early colorecta

Odds of Burnout Higher for Doctors Working With Incompletely Staffed Team

Working with an incompletely staffed team is associated with greater odds of burnout for physicians, according to a research letter published online May 14 in J

FDA Grants Accelerated Approval to Emrelis (telisotuzumab vedotin-tllv) for Non-Small Cell Lung Cancer With High c-Met Protein Overexpression